Consistent rotationnot site selectionis what keeps your skin healthy and your medication working as intended over the long term
Other Double Agonists and Triple Agonist Beyond tirzepatide, pharmaceutical companies have developed additional dual receptor agonists targeting GLP-1 and glucagon (GCG) as well as triple receptor agonists.210 Mazdutide represents the most recent advancement in GLP-1/GCG dual receptor agonists;211213 this agent, co-developed by Cinda Biology and Lilly Pharmaceutical, received marketing approval in China on June 27, 2025
Your GP can: Assess your current weight, BMI, and metabolic health to determine clinical need Review existing treatment options that are currently licensed and available in the UK, which may include orlistat, naltrexone/bupropion (Mysimba), semaglutide 2.4 mg (Wegovy approved by the MHRA for weight management and subject to NICE guidance on eligibility, service setting, and treatment duration), and tirzepatide (Mounjaro check current MHRA and NICE status at the time of reading, as licensing and commissioning arrangements may have been updated) Discuss eligibility for NHS Tier 3 or Tier 4 specialist weight management services , in line with NICE guidance on obesity management, where pharmacotherapy is used as an adjunct to structured lifestyle intervention Signpost you to relevant clinical trials via the Be Part of Research portal or ClinicalTrials.gov if you wish to explore participation in retatrutide research It is important to approach information about investigational medicines with appropriate caution
Pregnancy or breastfeeding: Do not use
While research is still evolving, some studies suggest these eating patterns may positively influence hormones involved in metabolism, including GLP-1
)
